Bronchoscopic instillation of DNase to manage refractory lobar atelectasis in a lung cancer patient.

Lobar atelectasis is a common complication in lung cancer. It can be caused by direct endobronchial tumorous seeding or indirectly by mucus plugs due to bacterial lung infections. Treatment is usually conservative, with or without therapeutic bronchoscopy. Dornase alfa is a recombinant human deoxyribonuclease I (rhDNase), an enzyme that selectively cleaves DNA, thus reducing mucous viscosity. rhDNase has been used as a mucolytic agent in cystic fibrosis (CF) patients. Though bronchoscopically instilled rhDNase has been reported as a treatment for persistent lobar atelectasis in newborn and pediatric populations, its use in adults has not been well established.

[1]  J. Marini.  Acute Lobar Atelectasis , 2019, Chest.

[2]  Ashley Johnson,et al.  Dornase Alfa for Non–Cystic Fibrosis Pediatric Pulmonary Atelectasis , 2014, The Annals of pharmacotherapy.

[3]  M. Uğurlucan,et al.  Safety of recombinant human deoxyribonuclease as a rescue treatment for persistent atelectasis in newborns , 2012, Annals of Saudi medicine.

[4]  D. Peckham,et al.  Sequential bronchoscopy in the management of lobar atelectasis secondary to allergic bronchopulmonary aspergillosis. , 2011, Journal of bronchology & interventional pulmonology.

[5]  Y. Bulbul,et al.  Pulmonary atelectasis and survival in advanced non-small cell lung carcinoma , 2010, Upsala journal of medical sciences.

[6]  J. Egan,et al.  Treatment of lobar atelectasis with bronchoscopically administered recombinant human deoxyribonuclease in cystic fibrosis? , 2008, The clinical respiratory journal.

[7]  M. Lequin,et al.  DNase and atelectasis in non-cystic fibrosis pediatric patients , 2005, Critical care.

[8]  D. Waltz,et al.  Bronchoscopically administered recombinant human DNase for lobar atelectasis in cystic fibrosis * , 2001, Pediatric pulmonology.

[9]  R. Ahrens,et al.  Aerosol delivery and safety of recombinant human deoxyribonuclease in young children with cystic fibrosis: a bronchoscopic study. Pulmozyme Pediatric Broncoscopy Study Group. , 1998, The Journal of pediatrics.

[10]  J. Zahm,et al.  Physical and functional properties of airway secretions in cystic fibrosis--therapeutic approaches. , 1995, Respiration; international review of thoracic diseases.

[11]  H. Fuchs,et al.  Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. , 1994, The New England journal of medicine.

[12]  S. Shak,et al.  Recombinant human DNase inhalation in normal subjects and patients with cystic fibrosis. A phase 1 study. , 1992, JAMA.